Evidence map›Paper›PMID 40301247›Full record

ArticleMolecular neurobiology2025

Repurposing Antidiabetic Drugs for Cerebrovascular Diseases: Causal Evidence from Drug Target Mendelian Randomization and Colocalization.

Xiangfeng Huang, Bo Yin, Qingzhou Hu, Qinbo Zheng, Bingbing Chen, Jiale Wang, Xinyu Ji, Kun Su

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiangfeng HuangWenzhou Medical University, Zhejiang, China.
Bo YinSecond Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang, China. 76yinbo@163.com.
Qingzhou HuWenzhou Medical University, Zhejiang, China.
Qinbo ZhengWenzhou Medical University, Zhejiang, China.
Bingbing ChenWenzhou Medical University, Zhejiang, China.
Jiale WangWenzhou Medical University, Zhejiang, China.
Xinyu JiWenzhou Medical University, Zhejiang, China.
Kun SuWenzhou Medical University, Zhejiang, China.

Funding

the Beijing New Health Industry Development Foundation XM2020-02-002
6 · The paper itself

Abstract

Cerebrovascular diseases have caused substantial social and economic burdens, and new treatment methods are urgently needed. Evaluating the feasibility of the use of antidiabetic drugs for treating cerebrovascular diseases is meaningful in this field. We designed a comprehensive study process that includes two-sample Mendelian randomization (MR), which uses genetic proxies for antidiabetic drug targets, summary-based MR (SMR) for mRNAs, and colocalization for drug target genes to assess their causal relationships with 10 cerebrovascular disease phenotypes. Seven of the eight main types of clinical antidiabetic drugs were identified, yielding eleven potential drug targets. Our study observed that sulfonylureas (KCNJ11) and metformin (GPD1) reduce the risk of stroke and that TZDs (PPARG) reduce the risk of hippocampal perivascular spaces. In addition, sulfonylureas can reduce the risk of certain cerebral small vessel disease. These results show that antidiabetic drugs have hypoglycemic properties and affect cerebrovascular health. Our study supports repurposing antidiabetic drugs as disease-modifying therapies to improve cerebrovascular health. Future research should focus on studying the role of drugs in different phenotypes of cerebrovascular diseases and explore the potential molecular mechanisms to analyze further the potential effects of antidiabetic drugs on cerebrovascular diseases.

Indexed as

Cerebrovascular DisordersDrug RepositioningHypoglycemic AgentsMendelian Randomization AnalysisHumansHypoglycemic AgentsAntidiabetic drugsCerebrovascular diseasesColocalizationDrug targetsGene expressionMendelian randomization

Identifiers

PMID40301247

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.